Zytiga is the older of the two drugs and was used in the active control arm of the ACIS study, which tested the combination of Erleada (apalutamide) and Zytiga (abiraterone) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).
Erleada is an androgen receptor inhibitor and is intended to counter the threat of Zytiga generics and competition from Astellas and Pfizer’s arch-rival Xtandi (enzalutamide), which has been on the market since 2012.
